Dimitri Kryndushkin

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Immunogenicity can have devastating consequences on the safety and efficacy of therapeutic proteins. Therefore, evaluating and mitigating the risk of product immunogenicity is critical for the development these products. This study, showed that Betaseron and Extavia, which are reported to be more immunogenic among IFNβ products in clinical usage, contain(More)
  • 1